
Opinion|Videos|February 27, 2026
Key Communication Strategies in EGFR+ NSCLC Management
Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss communication strategies between specialists and patients in EGFR-mutated NSCLC management.
Advertisement
Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, explore communication approaches that facilitate shared decision-making in EGFR-mutated non–small cell lung cancer. Florez emphasizes tailoring discussions to patient health literacy and cultural context to ensure treatment understanding and engagement. McDonald highlights practical techniques for reinforcing education during follow-up visits and maintaining clear communication across the care team.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article

Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, being evaluated in pancreatic ductal adenocarcinoma.

ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.

PLN-101095 earned an FDA fast track designation in combination with pembrolizumab for solid tumors resistant to immune checkpoint inhibitors.

Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.

Harold P. Freeman, MD, pioneer of patient navigation and cancer disparities research, has died at 93. He spent decades bridging gaps in cancer care access.

Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.

Dana M. Chase, MD, and Angeles Alvarez Secord, MD, MHSc, discuss mocertatug rezetecan in gynecologic malignancies.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
Updated SERENA-6 Data Sharpen the Debate on Early ctDNA-Guided Switching in Advanced Breast Cancer
3
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
4
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
5

